
Daniel Bui
Examiner (ID: 8414, Phone: (571)272-2618 , Office: P/2912 )
| Most Active Art Unit | 2912 |
| Art Unit(s) | 2912 |
| Total Applications | 4278 |
| Issued Applications | 4257 |
| Pending Applications | 0 |
| Abandoned Applications | 21 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16961633
[patent_doc_number] => 20210213132
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => FORMULATIONS OF SN-38 WITH POLY(AMINO ACID) BLOCK POLYMERS
[patent_app_type] => utility
[patent_app_number] => 17/142757
[patent_app_country] => US
[patent_app_date] => 2021-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8105
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17142757
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/142757 | Formulations of SN-38 with poly(amino acid) block polymers | Jan 5, 2021 | Issued |
Array
(
[id] => 19011652
[patent_doc_number] => 11918552
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-05
[patent_title] => N-acetylcysteine for use as antibacterial agent
[patent_app_type] => utility
[patent_app_number] => 17/134719
[patent_app_country] => US
[patent_app_date] => 2020-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2203
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17134719
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/134719 | N-acetylcysteine for use as antibacterial agent | Dec 27, 2020 | Issued |
Array
(
[id] => 16749869
[patent_doc_number] => 20210101878
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-08
[patent_title] => Cannabinergic Compounds And Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/119836
[patent_app_country] => US
[patent_app_date] => 2020-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43867
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17119836
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/119836 | Cannabinergic compounds and uses thereof | Dec 10, 2020 | Issued |
Array
(
[id] => 16718532
[patent_doc_number] => 20210085679
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-25
[patent_title] => PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA
[patent_app_type] => utility
[patent_app_number] => 17/115317
[patent_app_country] => US
[patent_app_date] => 2020-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17554
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17115317
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/115317 | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria | Dec 7, 2020 | Issued |
Array
(
[id] => 17768182
[patent_doc_number] => 11400100
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-02
[patent_title] => Effective benzalkonium chloride-free bimatoprost ophthalmic compositions
[patent_app_type] => utility
[patent_app_number] => 17/115001
[patent_app_country] => US
[patent_app_date] => 2020-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 23508
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 139
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17115001
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/115001 | Effective benzalkonium chloride-free bimatoprost ophthalmic compositions | Dec 7, 2020 | Issued |
Array
(
[id] => 17272768
[patent_doc_number] => 20210378966
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => ADDITIVE COMPOSITION FOR FORMULATION CAPABLE OF STABILIZING PORE OF SOLID PARTICLES AND METHOD FOR PRODUCTION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/298723
[patent_app_country] => US
[patent_app_date] => 2020-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5658
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17298723
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/298723 | Additive composition for formulation capable of stabilizing pore of solid particles and method for production thereof | Dec 2, 2020 | Issued |
Array
(
[id] => 19649969
[patent_doc_number] => 12171729
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-24
[patent_title] => Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors
[patent_app_type] => utility
[patent_app_number] => 17/779048
[patent_app_country] => US
[patent_app_date] => 2020-11-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 46
[patent_figures_cnt] => 49
[patent_no_of_words] => 15094
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779048
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/779048 | Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors | Nov 24, 2020 | Issued |
Array
(
[id] => 16853420
[patent_doc_number] => 20210154165
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-27
[patent_title] => TARGETING OF ARID1A-DEFICIENT CANCERS BY INHIBITING DE NOVO PYRIMIDINE SYNTHESIS PATHWAY
[patent_app_type] => utility
[patent_app_number] => 17/102992
[patent_app_country] => US
[patent_app_date] => 2020-11-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19573
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17102992
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/102992 | Targeting of ARID1A-deficient cancers by inhibiting de novo pyrimidine synthesis pathway | Nov 23, 2020 | Issued |
Array
(
[id] => 17124357
[patent_doc_number] => 20210299125
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => CERDULATINIB FOR TREATING MYELOMA
[patent_app_type] => utility
[patent_app_number] => 17/092137
[patent_app_country] => US
[patent_app_date] => 2020-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6796
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17092137
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/092137 | Cerdulatinib for treating myeloma | Nov 5, 2020 | Issued |
Array
(
[id] => 16619895
[patent_doc_number] => 20210038548
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-11
[patent_title] => COMPOSITION AND METHOD FOR COMPOUNDED THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/080491
[patent_app_country] => US
[patent_app_date] => 2020-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13820
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17080491
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/080491 | COMPOSITION AND METHOD FOR COMPOUNDED THERAPY | Oct 25, 2020 | Abandoned |
Array
(
[id] => 18233184
[patent_doc_number] => 11597733
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-03-07
[patent_title] => Compounds and compositions for the treatment of parasitic diseases
[patent_app_type] => utility
[patent_app_number] => 17/076126
[patent_app_country] => US
[patent_app_date] => 2020-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 60006
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17076126
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/076126 | Compounds and compositions for the treatment of parasitic diseases | Oct 20, 2020 | Issued |
Array
(
[id] => 19186177
[patent_doc_number] => 20240165090
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-23
[patent_title] => METHODS AND COMPOSITIONS FOR IMPROVING BONE MARROW HEMATOPOIETIC FUNCTIONS
[patent_app_type] => utility
[patent_app_number] => 17/769672
[patent_app_country] => US
[patent_app_date] => 2020-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24439
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769672
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/769672 | METHODS AND COMPOSITIONS FOR IMPROVING BONE MARROW HEMATOPOIETIC FUNCTIONS | Oct 15, 2020 | Pending |
Array
(
[id] => 18056324
[patent_doc_number] => 20220387410
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal
[patent_app_type] => utility
[patent_app_number] => 17/772705
[patent_app_country] => US
[patent_app_date] => 2020-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8293
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17772705
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/772705 | 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal | Oct 15, 2020 | Pending |
Array
(
[id] => 18056324
[patent_doc_number] => 20220387410
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal
[patent_app_type] => utility
[patent_app_number] => 17/772705
[patent_app_country] => US
[patent_app_date] => 2020-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8293
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17772705
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/772705 | 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal | Oct 15, 2020 | Pending |
Array
(
[id] => 16612105
[patent_doc_number] => 20210030758
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => TREATMENT OF CANCERS HAVING DRIVING ONCOGENIC MUTATIONS
[patent_app_type] => utility
[patent_app_number] => 17/067549
[patent_app_country] => US
[patent_app_date] => 2020-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26958
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -51
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17067549
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/067549 | TREATMENT OF CANCERS HAVING DRIVING ONCOGENIC MUTATIONS | Oct 8, 2020 | Abandoned |
Array
(
[id] => 16718537
[patent_doc_number] => 20210085684
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-25
[patent_title] => PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/067588
[patent_app_country] => US
[patent_app_date] => 2020-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30166
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17067588
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/067588 | PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES | Oct 8, 2020 | Abandoned |
Array
(
[id] => 18801401
[patent_doc_number] => 11834553
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-05
[patent_title] => Alkoxylation methods
[patent_app_type] => utility
[patent_app_number] => 17/062457
[patent_app_country] => US
[patent_app_date] => 2020-10-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 30326
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 189
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17062457
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/062457 | Alkoxylation methods | Oct 1, 2020 | Issued |
Array
(
[id] => 18368074
[patent_doc_number] => 11648221
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-16
[patent_title] => KRAS agonists, pharmaceutical compositions, and uses in managing cancer
[patent_app_type] => utility
[patent_app_number] => 17/034908
[patent_app_country] => US
[patent_app_date] => 2020-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 19
[patent_no_of_words] => 10503
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17034908
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/034908 | KRAS agonists, pharmaceutical compositions, and uses in managing cancer | Sep 27, 2020 | Issued |
Array
(
[id] => 18716494
[patent_doc_number] => 11793816
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-24
[patent_title] => Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B
[patent_app_type] => utility
[patent_app_number] => 17/017351
[patent_app_country] => US
[patent_app_date] => 2020-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 8
[patent_no_of_words] => 9781
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17017351
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/017351 | Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B | Sep 9, 2020 | Issued |
Array
(
[id] => 17865298
[patent_doc_number] => 20220288033
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => HETEROCYCLIC COMPOUNDS AS MODULATORS OF BETA-CATENIN / TCF4 INTERACTION
[patent_app_type] => utility
[patent_app_number] => 17/639634
[patent_app_country] => US
[patent_app_date] => 2020-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14382
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17639634
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/639634 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BETA-CATENIN / TCF4 INTERACTION | Sep 2, 2020 | Pending |